Qilu Pharmaceutical has an integrated innovation system which includes the Qilu Drug Resarch Institute, a research department in each subsidiary, and innovative technical equipment for every team responsible for researching new drugs and for improving manufacturing processes. In total, there are 800 employees involved in the Qilu Drug Research Institute, the majority of whom are highly qualified researchers.
Qilu Drug Research Institute is the key research unit within the Qilu Group. Over the past 20 years it has obtained over 120 certificates for new drugs, over 100 patents, has been granted 40 technology awards and currently has underway 17 national projects relating to new drug research. This means a total of over 100 new drugs in our product portfolio.
In addition, in 2014, the Company began the construction of a Biotechnology Park, the first phase of which is expected to be complete in 2016 with an initial investment of 150 million euros on a surface area of 110,000 m².
Manufacturing lines have been established in accordance with the FDA (Food and Drug Administration) / EMA (European Directorate for the Quality of Medicines) for the production of biological medicines.